Abstract-The first aim of our study was to develop a pregnant mouse model for preeclampsia using adenoviral vector containing mouse full-length soluble fms-like tyrosine kinase 1 (sFlt-1) but not truncated sFlt-1. The second aim was to evaluate effects of recombinant mouse (rm) vascular endothelial growth factor (VEGF) and rm placental growth factor (PlGF) on a preeclampsia model induced by adenoviral vector containing mouse full-length sFlt-1. We injected adenoviral vector containing mouse full-length sFlt-1 on day 8.5 or 9.5 of gestation into pregnant Institute of Cancer Research mice, resulting in hypertension, proteinuria, and similar glomerular histological changes as those seen in human preeclamptic women with glomerular endotheliosis on day 16.5 or 17.5 of gestation. The preeclampsia models were treated with 100 g/kg of rmVEGF164 (nϭ5), 100 g/kg of rmPlGF-2 (nϭ5), or vehicle (nϭ7) twice a day for 2 days IP. The rmVEGF164 treatment significantly decreased the mean blood pressure on day 16.5 or 17.5 of gestation compared with the vehicle treatment (85Ϯ4 versus 97Ϯ2 mm Hg; Pϭ0.018). The rmPlGF-2 treatment also significantly decreased the mean blood pressure on day 16.5 or 17.5 of gestation compared with the vehicle treatment (86Ϯ3 versus 97Ϯ2 mm Hg; Pϭ0.018). However, proteinuria was not affected by either rmVEGF164 or rmPlGF-2. In conclusion, we, for the first time, created a mouse preeclampsia model using mouse full-length sFlt-1. VEGF and PlGF may be promising for ameliorating hypertension in women with preeclampsia. Additional study of PlGF as a potential drug for preeclampsia is warranted. Key Words: adenoviral vector Ⅲ soluble fms-like tyrosine kinase 1 Ⅲ vascular endothelial growth factor Ⅲ placental growth factor Ⅲ preeclampsia Ⅲ animal models Ⅲ therapy P reeclampsia is associated with maternal and infantile morbidity and mortality. 1,2 It has been shown that the concentration of soluble fms-like tyrosine kinase 1 (sFlt-1), a circulating antiangiogenic protein, is increased in women with preeclampsia, 3,4 and increased levels of sFlt-1 and reduced levels of free placental growth factor (PlGF) are potentially useful for predicting the subsequent development of preeclampsia. 4,5 SFlt-1 acts by adhering to the receptorbinding domains of vascular endothelial growth factor (VEGF)-A and PlGF, preventing their interaction with endothelial receptors on the cell surface. Recent studies have indicated that patients with cancer receiving anti-VEGF antibody therapy may have an increased incidence of proteinuria and hypertension because of a decrease in their circulating VEGF levels. 6 Nonpregnant and pregnant rodents administered anti-VEGF antibodies or sFlt-1 manifested proteinuria and hypertension. 3,7,8 These results strongly indicate that increases in sFlt-1 and decreases in VEGF/PlGF in the maternal circulation may cause the occurrence of preeclampsia.
P reeclampsia is associated with maternal and infantile morbidity and mortality. 1, 2 It has been shown that the concentration of soluble fms-like tyrosine kinase 1 (sFlt-1), a circulating antiangiogenic protein, is increased in women with preeclampsia, 3, 4 and increased levels of sFlt-1 and reduced levels of free placental growth factor (PlGF) are potentially useful for predicting the subsequent development of preeclampsia. 4, 5 SFlt-1 acts by adhering to the receptorbinding domains of vascular endothelial growth factor (VEGF)-A and PlGF, preventing their interaction with endothelial receptors on the cell surface. Recent studies have indicated that patients with cancer receiving anti-VEGF antibody therapy may have an increased incidence of proteinuria and hypertension because of a decrease in their circulating VEGF levels. 6 Nonpregnant and pregnant rodents administered anti-VEGF antibodies or sFlt-1 manifested proteinuria and hypertension. 3, 7, 8 These results strongly indicate that increases in sFlt-1 and decreases in VEGF/PlGF in the maternal circulation may cause the occurrence of preeclampsia.
SFlt-1, a human natural soluble form of the VEGF receptor (VEGFR) 1, is produced in conditioned culture medium of human umbilical vein endothelial cells 9 and in the trophoblasts. 10, 11 SFlt-1 is encoded by the flt-1 gene and is truncated between N-terminal immunoglobulin-like domains 6 and 7. 12 Because the N-terminal first and second domains of Flt-1 are necessary and sufficient for the binding of VEGF-A with near-native affinity, 13, 14 truncated sFlt-1 [1] [2] [3] containing the first to third domains, but not full-length sFlt-1, has been used for the studies evaluating the effect of sFlt-1 on hypertension and proteinuria in mouse or rat models. 3, 7, [15] [16] [17] [18] [19] However, there are 2 differences between the full-length sFlt-1 and truncated sFlt-1 [1] [2] [3] : first, the full-length sFlt-1 has a 31-amino acid carboxyl lesion derived from an intron, which is significantly homologous to that in mammals, 11 and, second, the truncated sFlt-1 1-3 lacks the immunoglobulin-like loop 4, which is essential to stabilize receptor dimerization of the extracellular domains of Flt-1, in addition to VEGF. 13, 14 Therefore, the effect of sFlt-1 on the occurrence of hyperten-sion or proteinuria may be different between truncated sFlt-1 and natural full-length sFlt-1.
It has been reported that the effect of excess circulating sFlt-1 can be ameliorated by the administration of recombinant VEGF-A. 7, 19 However, in humans, a decrease in PlGF is related to the later occurrence of preeclampsia. 20 -22 Therefore, we also hypothesized that not only VEGF-A, but also PlGF, may play a pivotal role in the occurrence of hypertension and proteinuria in both humans and rodents. To our knowledge, the effect of the administration of PlGF into a rodent model of preeclampsia via a mouse (m)-sFlt-1 adenoviral vector has not been examined.
First, we evaluated an adenovirus encoding the full-length mouse-sFlt-1 gene (Ad m-sFlt-1) for the induction of hypertension and proteinuria in pregnant mice. Second, we evaluated the effects of recombinant mouse (rm) VEGF164 (rm-VEGF164) and rmPlGF-2 on hypertension and proteinuria in a mouse preeclampsia model induced by Ad m-sFlt-1.
Methods
An expanded Materials and Methods section is available in the online Data Supplement (available at http://hyper.ahajounals.org). Briefly, in the first experiment, an Ad m-sFlt-1, which was created in our previous study, 23 and an adenovirus encoding ␤-galactosidase gene (Ad LacZ) were propagated in HEK293cells. The viral lysates were purified and concentrated through 2 cycles of CsCl step gradients. 24 Nine-to 12-week-old CD1 (Institute of Cancer Research) mice were injected in the tail vein with 3ϫ10 8 plaque-forming unit (PFUs; low dose), 1ϫ10 9 PFUs (medium dose), or 2ϫ10 9 PFUs (high dose) of Ad m-sFlt-1 (nϭ9, nϭ6, and nϭ6, respectively) and with 3ϫ10 8 PFUs (low dose), 1ϫ10 9 PFUs (medium dose), or 2ϫ10 9 PFUs (high dose) of Ad LacZ (nϭ7, nϭ6, and nϭ7, respectively) on day 8.5 or 9.5 of gestation. The control pregnancy mice were not injected with anything (nϭ7). The mean blood pressures (MBPs) were measured by the tail-cuff method (Softron Ltd) on 4 different days: (1) before mating, (2) just before the injection of adenovirus, (3) on day 13.5 or 14.5 of gestation, and (4) on day 16.5 or 17.5 of gestation. The urine albumin:creatinine (Alb/Cre) ratios on day 16.5 or 17.5 of gestation were measured. In the second experiment, pregnant mice were injected in their tail vein with 2ϫ10 9 PFUs (high dose) of Ad m-sFlt-1 on day 8.5 or 9.5 of gestation. rmVEGF164 (100 g/kg diluted in 500 L of PBS; nϭ5) was administered IP twice a day for 2 days from the evening on day 14.5 or 15.5 of gestation. In other mice, rmPlGF-2 (100 g/kg diluted in 500 L of PBS; nϭ5) and the vehicle (500 L of PBS; nϭ7) were administered IP twice a day for 2 days. The MBP and Alb/Cre ratio were also measured. All of the animal housing and experiments were approved by the institutional animal care and research advisory committee of both the University of Tohoku and Jichi Medical University. The pharmacokinetics of rmVEGF164 and rmPlGF-2 in nonpregnant mice and pregnant mice are shown in the online Data Supplement (available at http://hyper.ahajournals.org, Figure S1A through S1D).
Results

Expression of Proteins by the Adenoviral Vector
In mice administered Ad LacZ, ␤-galactosidase activity was observed in the liver but not in the placenta by 5-bromo-4-chloro-3-indolyl ␤-D-galactoside staining, suggesting that Ad m-sFlt-1 was expressed in the liver. Figure  1A ). The levels of mouse sFlt-1 on day 16.5 or 17.5 of gestation were not different among the control and the mice administered the low, medium, and high dose of Ad LacZ (Pϭ0.76 by Kruskal-Wallis test).
Plasma Levels of Angiogenic Factors in Mice Administered Ad m-sFlt-1
The plasma levels of mouse VEGF-A (picograms per milliliter) on day 16.5 or 17.5 of gestation in the mice administered high-dose Ad m-sFlt-1 were significantly lower than in the mice administered high dose Ad LacZ (47 [43 to 52] versus 95 [93 to 113]; Pϭ0.001; Figure 1B) . On the contrary, the levels of mouse PlGF-2 (picograms per milliliter) on day 16.5 or 17.5 of gestation were almost the same among the control mice, the high-dose Ad LacZ group, and the highdose Ad m-sFlt-1 group (21 [ Figure 1C ).
Blood Pressure and Proteinuria in Pregnant Mice Administered Ad m-sFlt-1
In the control mice and the mice administered low, medium, and high doses of Ad LacZ, MBP (millimeters of mercury) was almost the same during the prepregnancy period and during pregnancy ( Figure 1D ). In the mice administered high-dose Ad m-sFlt-1, MBP was significantly increased between day 8.5 or 9.5 and day 13.5 or 14.5 (76Ϯ2 versus 91Ϯ4; Pϭ0.028) and between day 13.5 or 14.5 and day 16.5 or 17.5 (91Ϯ4 versus 101Ϯ3; Pϭ0.028), although such increases were not seen in the mice administered low or medium doses of Ad m-sFlt-1 ( Figure  1E ). The MBP on day 16.5 or 17.5 of gestation in the high-dose Ad m-sFlt-1 group was significantly higher than that in the high-dose Ad LacZ group (101Ϯ3 versus 81Ϯ11; Pϭ0.010) and the control group (83Ϯ4; Pϭ0.005). The urine Alb/Cre ratios (milligrams per gram) on day 16.5 or 17.5 of gestation in the mice administered low, medium, and high doses of Ad m-sFlt-1 were significantly increased compared with those in the mice administered low, medium, and high doses of Ad LacZ, respectively (5. Figure 1F ).
Histopathology in Mice Administered Ad m-sFlt-1
Glomerular histologies viewed by light microscopy in mice administered high-dose Ad m-sFlt-1 ( Figure S2D and S2E) and those in the mice administered high-dose Ad LacZ ( Figure S2A and S2B), scanning electron microscopy of glomerulus in mice administered high-dose Ad m-sFlt-1 and Ad Lac Z ( Figure S2F and S2C) , and the mean fetal and placental weights among the control mice, the highdose Ad LacZ group, and the high-dose Ad m-sFlt-1 group ( Figure S2G and S2H) were shown in the online Data Supplement. These results were written in the online Data Supplement.
inverse relationship between the plasma levels of log10sFlt-1 and log10VEGF-A (rϭϪ0.29; Pϭ0.042; Figure 2A) ; positive relationships between the plasma levels of log10sFlt-1 and MBP (rϭ0.24; Pϭ0.098; Figure 2B ) and between the plasma levels of log10sFlt-1 and urine log10(Alb/Cre; rϭ0.44; Pϭ0.002; Figure 2C ); and inverse relationships between the plasma levels of log10VEGF-A and MBP (rϭϪ0.33; Pϭ0.023; Figure 2D ) and between the plasma levels of log10VEGF-A and urine log10(Alb/Cre; rϭϪ0.44; Pϭ0.002; Figure 2E ). Thus, the circulating levels of sFlt-1 are significantly positively related to the degree of proteinuria, whereas the circulating levels of VEGF-A are significantly inversely related to both blood pressure and proteinuria. Our results indicate that decreased levels of circulating VEGF-A cause the increases in blood pressure seen in the mice administered Ad m-sFlt-1. .5 of gestation, on day 13.5 or 14.5 of gestation, and on day 16.5 or 17.5 of gestation. ࡗ, Ⅺ, ‚, and E represent the values in the control pregnant mice and pregnant mice administered low-dose (3ϫ10 8 PFU), medium-dose (1ϫ10 9 PFU), and high-dose (2ϫ10 9 PFU) Ad LacZ, respectively. E, MBP (millimeters of mercury) during the prepregnancy period, on day 8.5 or 9.5 of gestation, on day 13.5 or 14.5 of gestation, and on day 16.5 or 17.5 of gestation. E, f, OE, and F represent the values in pregnant mice administered high-dose Ad LacZ and mice administered low-dose, medium-dose, and high-dose Ad m-sFlt-1, respectively. F, Urine Alb/Cre ratios (milligrams per gram) on day 16.5 or 17.5 of gestation. *PϽ0.05; **PϽ0.01.
Effects of rmVEGF164 and rmPlGF-2 in Mice Administered High-Dose Ad m-sFlt-1
In pregnant mice administered high-dose Ad m-sFlt-1 compared with mice administered vehicle, the levels of mouse VEGF-A (pg/ml) 3 to 4 hours after the last administration of rmVEGF164 were significantly increased (356 [121 to 793] versus 59 [56 to 68]; Pϭ0.010; Figure 3A ), and the level of mouse PlGF-2 (pg/ml) 3 to 4 hours after the last administration of rmPlGF-2 was also significantly increased (244 [133 to 244] versus 60 [52 to 74]; Pϭ0.010; Figure 3B ).
The rmVEGF164 treatment significantly decreased the MBP (mm Hg) on day 16.5 or 17.5 of gestation compared with the vehicle treatment (85Ϯ4 versus 97Ϯ2; Pϭ0.018; Figure 3C ). The rmPlGF-2 treatment also significantly decreased the MBP on day 16.5 or 17.5 of gestation compared with the vehicle treatment (86Ϯ3 versus 97Ϯ2; Pϭ0.018). However, the urine Alb/Cre levels were not affected by treatment with either rmVEGF164 or rmPlGF-2 ( Figure 3D ). The rmVEGF164 treatment and rmPlGF-2 treatment did not ameliorate glomerular histology viewed by light microscopy in pregnant mice administered high-dose Ad m-sFlt-1 compared with those administered vehicle.
Discussion
In this study, we created a pregnant mouse model of preeclampsia, showing hypertension, proteinuria, and glomerular change, like endotheliosis, by transfecting a high dose (2ϫ10 9 PFUs) of adenovirus encoding full-length m-sFlt-1. In addition, we revealed that rmVEGF164 and rmPlGF-2 ameliorate the hypertension induced by the administration of a high dose of Ad m-sFlt-1 in pregnant mice.
Development of a Pregnant Mouse Model of Preeclampsia Using Ad m-sFlt-1 and the Relationships Between the Serum Levels of m-sFlt-1/m-VEGF-A/mPlGF-2 and Hypertension/Proteinuria
We, for the first time, created a mouse preeclampsia model using full-length m-sFlt-1 instead of truncated m-sFlt-1, which has been used in previous mouse preeclampsia models. 3, 7, [15] [16] [17] [18] [19] In the previous rat models using truncated m-sFlt-1, both hypertension and proteinuria emerged after low-dose (1ϫ10 8 -PFU) administration of Ad m-sFlt-1. 3 On the contrary, we needed a higher dose of Ad m-sFlt-1 to generate both hypertension and proteinuria. In our study, increases in the plasma levels of sFlt-1 were related to the occurrence of proteinuria, and decreases in the plasma levels of VEGF-A were related to the occurrence of both hypertension and proteinuria. Therefore, the circulating levels of sFlt-1 and VEGF-A may be important for the occurrence of hypertension and proteinuria. It is possible that the in vivo expression of sFlt-1 in the liver per administered dose of adenovirus or the circulating levels of sFlt-1 or VEGF-A were different between the 2 studies.
It is well known that the administration of sFlt-1 into rodents results in the occurrence of proteinuria. 3 et al 25 reported that proteinuria, but not hypertension, emerged in nonpregnant mice administered adenovirustruncated m-sFlt-1. Sugimoto et al 7 reported that IV administration of an sFlt-1/Fc chimera protein into nonpregnant mice resulted in proteinuria 3 hours after the administration. Maynard et al 3 reported that IV administration of adenovirustruncated m-sFlt-1 into nonpregnant and pregnant rats resulted in severe proteinuria. In addition, the effect of adenovirus-truncated m-sFlt-1 in pregnant rats on the occurrence of proteinuria was more severe than that of adenovirussoluble endoglin, both of which can cause both hypertension and proteinuria in pregnant mice. 16 However, the proteinuria presented in this mouse model is fairly modest compared with what is presented in the rats where the Alb/Cre ratio is frequently Ͼ1000 mg/g. 3 One possibility is that the dose using the full-length sFlt1 is not enough, because it tends to have a poor bioavailability in contrast to truncated sFlt1.
Another possibility is that proteinuria may depend on the background of the mouse strains used. In our experiment, the decrease in the circulating levels of VEGF-A, but not PlGF-2, was related to the increase in MBP. The effect of VEGF-A on blood pressure has been reported in humans. 26 -29 The blocking of signal transduction of VEGF-A by anti-VEGF monoclonal antibody 26, 27 and tyrosine kinase inhibitors, such as soraferib 28 and sumitinib, 29 induces hypertension. On the contrary, the administration of rmVEGF-A results in a decrease of MBP in rats. 30, 31 Thus, an appropriate circulating VEGF-A level appears to be important for the maintenance of normal blood pressure. Although the detailed mechanism by which a decreased level of VEGF-A affects the occurrence of hypertension has not been elucidated, the modulation of the production of NO by VEGF-A via endothelial NO synthase activity in endothelial cells may be related to the change in blood pressure. 32, 33 The mouse PlGF-2 was not altered in this mouse model of preeclampsia. The circulating levels of PlGF-1 are low in preeclamptic women, 3-5,19 -21 because the human ELISA assay measured free PlGF but not total PlGF. We could not know whether the assay of the mouse PlGF-2 in our study measured a free or total PlGF-2 assay. We speculate that the assay of the mouse VEGF-A measured a free VEGF-A and that the assay of the mouse PlGF-2 measured a total PlGF-2, because the levels of VEGF-A were decreased but the levels of PlGF-2 were not decreased by the administration of high-dose Ad m-sFlt-1.
Effect of rmVEGF164 and rmPlGF-2 on Blood Pressure and Proteinuria in a Pregnant Mouse Preeclampsia Model
We revealed that rmVEGF164 ameliorates the hypertension induced by the administration of a high dose of Ad m-sFlt-1 
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in pregnant mice. Li et al 19 reported the therapeutic effect of VEGF-A in preeclamptic rat models induced by the IV administration of truncated Ad m-sFlt-1 on 8 days of gestation; the SC administration of 800 g/kg per day of recombinant human VEGF121 for 6 days during day 11 to day 16 of gestation resulted in the amelioration of systolic blood pressure. In our study, the administered doses of rmVEGF164 were lower, and the treatment duration of rmVEGF164 was shorter compared with the study of Li et al 19 ; however, the MBP after the administration of rmVEGF164 decreased. Therefore, the administration of recombinant VEGF-A to women with preeclampsia may be an effective treatment for this condition, especially for women with early onset preeclampsia, in whom the delay of birth by weeks may contribute to the reduction of neonatal complications and neonatal stay in the newborn intensive care unit. 34 We, for the first time, revealed that rmPlGF-2 ameliorates the hypertension induced by high doses of Ad m-sFlt-1 in pregnant mice. To the best of our knowledge, this is the first experiment that showed the antihypertensive effect of rmPlGF on the hypertension induced by Ad m-sFlt-1 in pregnant mice. Hypotension induced by VEGF-A is mainly mediated by VEGFR2. 30 Because PlGF binds only to VEGFR1 and has little or no direct mitogenic or permeability-enhancing activity, 35, 36 we supposed that the hypotensive effect of PlGF is very weak. However, surprisingly, the antihypertensive effect of PlGF was as strong as the antihypertensive effect of VEGF-A in our preeclampsia mouse model. Recently, Osol et al 37 reported that PlGF had a vasodilatory effect on numerous arteries and veins in rats; pregnancy significantly enhanced sensitivity to PlGF in rat uterine arteries; the vasodilatory effect of PlGF during pregnancy was mainly attributed to the activation of VEGFR1 but not VEGFR2; VEGFR1 was upregulated in the uterine artery wall during gestation; and PlGF dilation was principally mediated by the release of NO in rat uterine arteries. In addition, Osol et al 37 also showed that both rat mesenteric and human SC arteries dilated in response to PlGF in an NO-independent manner. These observations clearly suggest that PlGF has the ability to dilate vessels during pregnancy; that is, PlGF has a potentially antihypertensive effect during pregnancy.
Possible Mechanism by Which Hypertension and Proteinuria Emerge in a Pregnant Mouse Administered Recombinant sFlt-1
Recently, Bridges et al 8 reported that placental and vascular superoxide productions were increased and plasma VEGF-A concentrations were decreased in pregnant rats administered recombinant sFlt-1 chronically during days 13 to 18 of gestation. Vasorelaxations to both acetylcholine and sodium nitroprusside were decreased in pregnant rats administered recombinant sFlt-1, and the decrease of vasorelaxation to acetylcholine was attenuated by the addition of the superoxide scavenger Tiron, indicating elevated maternal sFlt-1, via the decrease of VEGF, results in increased oxidative stress that contributes to vascular dysfunction during pregnancy. 8 VEGF contributes to the maintenance of an appropriate balance of pro-oxidant and antioxidant factors via manganese superoxide dismutase 38 and NADPH oxidase, 39 and regulates NO production. 32, 33 We also observed that the plasma VEGF levels were decreased in pregnant mice administered high doses of Ad m-sFlt-1 and the treatment of VEGF ameliorated hypertension induced by Ad m-sFlt-1. Therefore, increased oxidative stress and vascular dysfunction might be factors in hypertension in the present model, although we did not measure the oxidative stress. Taken together, VEGF antagonism may induce endothelial cell oxidative stress and contribute to renal dysfunction and hypertension.
Conclusions
We, for the first time, created a mouse preeclampsia model using full-length m-sFlt-1 instead of truncated m-sFlt-1, which has been used in previous mouse preeclampsia models. 3, 7, [15] [16] [17] [18] [19] Not only rmVEGF164, but also PlGF-2, ameliorated hypertension in the mouse preeclampsia model induce by full-length m-sFlt-1. Additional study of PlGF as a potential drug for preeclampsia is warranted.
Perspectives
Our study suggested a possible new therapy using PlGF for preeclamptic women. However, there are several unsolved issues. How many doses of PlGF-2 are sufficient for the amelioration of hypertension and proteinuria in the pregnant mouse model of preeclampsia using Ad m-sFlt-1? When should the administration of PlGF be started to restrict the occurrence of hypertension and proteinuria? What kinds of angiogenetic factors show the best therapeutic effects? In addition, if possible, we should make a mouse/rat model using adenoviral human sFlt-1, because the effect of m-sFlt-1 on mouse VEGF-A/PlGF might be different from that of human sFlt-1 on human VEGF-A/PlGF. If the human PlGF-1/PlGF-2 is used for the prevention/therapy of preeclampsia, we should carefully monitor the occurrence of possible adverse effects, such as lung edema, the development of new blood vessels in nontargeted tissues. 
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The effect of recombinant PlGF-2 on hypertension induced by full-length mouse sFlt-1 adenoviral vector in pregnant mice The control pregnancy mice were not injected with anything (n=7). Blood pressure was measured by the tail-cuff method (Softron Ltd, Tokyo, Japan) on 4 different days: (1) before mating, (2) just before the injection of Ad, (3) on day 13.5 or 14.5 of gestation, and (4) and the supernatants were stored at -80 °C. Some kidneys, liver, and placentas were stored at -80°C, and others were fixed in 4% paraformaldehyde overnight. In the control mice and mice administered high dose Ad m-sFlt-1, the kidneys were prepared for electron microscopy. The un-absorbed fetuses and placentas were counted and weighed.
β-galactosidase (X-gal) Staining
Frozen livers and placentas were stained using X-gal solution (X-Gal, Sigma and Aldorich Inc., Saint Louis, MO). When a sample is stained blue, it is judged that β-galactosidase is expressed in the tissue.
Enzyme-Linked ImmunoSorbent Assay (ELISA)
The plasma levels of mouse sFlt-1, mouse VEGF-A, and mouse PlGF-2 were measured by ELISA kits (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions.
Urine albumin was measured by an ELISA kit (Exocell Inc., Phila, PA), and urine creatinine was measured by the alkaline picrate method (Exocell Inc., Phila, PA) according to the manufacturer's instructions. The urine albumin / creatinine (Alb/Cre) ratio was used as an indicator of urinary proteinuria.
Histopathology
The samples of kidney, liver, and placenta fixed in 4% paraformaldehyde diluted by Dulbecco's phosphate buffered saline without containing calcium and magnesium (PBS, Nissui Pharmaceutical Co., Tokyo, Japan) were processed for paraffin embedding and sectioning. A series of 3.5 µm sections were cut and processed for hematoxylin & eosin (H&E) and periodic acid Schiff (PAS) staining.
The kidney samples were prepared for scanning electron microscopy, according to procedures previously reported in our study (3) and were examined using an H-7600 electron microscope (Hitachi High-Technologies Co., Tokyo, Japan).
The Pharmacokinetics of rmVEGF 164 and rmPlGF-2 in Non-Pregnant Mice and Pregnant Mice
The pharmacokinetics of rmVEGF 164 In non-pregnant mice, the levels of mouse VEGF-A peaked at 1 hour after the i.p.
administration of both 40 μg/kg and 200 μg/kg rmVEGF 164 , decreased gradually, and almost reached their initial levels 8 hours after the administration (Fig. S1A) . The levels in the mice In pregnant mice, the levels of mouse VEGF-A peaked at 1 hour after the i.p.
administration of 100 μg/kg rmVEGF 164 , decreased gradually, and almost reached their initial levels 8 hours after the administration (Fig. S1C) . The plasma half-life of VEGF 164 was 1.79
hr. The level of mouse PlGF-2 also peaked at 1 hour after the i.p. administration of 100 μg/kg rmPlGF-2, gradually decreased, and almost reached its initial level 24 hours after the administration (Fig. S1D) . The plasma half-life of PlGF-2 was 1.88 hr. sacrificed. Blood samples were collected, and the supernatants were stored at -80 °C.
Statistics
Normally distributed data are represented as means ± SE; data that were not normally distributed are represented as medians with interquartile ranges. Student's unpaired and paired t-tests, and the Mann-Whitney U test and Wilcoxon signed ranks test were used as appropriate.
Regression analyses were performed among the levels of sFlt-1, VEGF-A, MBP, and urine Alb/Cre ratio, after the logarithmic transformation of the levels of sFlt-1, VEGF-A, and urine Alb/Cre ratio. A level of p <0.05 was considered statistically significant.
Results
Histopathology in Mice Administered Ad m-sFlt-1
Glomerular histology viewed by light microscopy in mice administered high dose Ad m-sFlt-1
showed capillary occlusions and numerous PAS positive areas (Fig. S2D, S2E ) compared with that in the mice administered high dose Ad LacZ (Fig. S2A, S2B ). On the contrary, there were no significant histopathological changes in the liver or placental tissue among all groups (data not shown). Scanning electron microscopy revealed a thicker endothelium and the reduction of endothelial fenestrations in the glomerular endothelium in the mice administered high dose Ad m-sFlt-1, although no increase in mesangial cells or changes in foot processes were identified (Fig. S2C, S2F ). The mean fetal and placental weights were not different among the control mice, high dose Ad LacZ group, and high dose Ad m-sFlt-1 group (Fig. S2G, S2H ).
Discussion
Glomerular changes in pregnant mouse preeclampsia model
Our pregnant mice administered high dose Ad m-sFlt-1 exhibited glomerular endothelial hypertrophy and a reduction of endothelial fenestrations, although no increase in mesangial cells or changes in foot processes were identified. These changes were similar to the glomerular endotheliosis changes seen in humans, which are characteristic lesions found in renal biopsies from preeclamptic women and are considered pathognomonic for the condition (4, 5) . It has been reported that the blocking of VEGF-A signaling causes dysfunctions in endothelial cells and podocytes and that the collapse of the glomerular filtration barrier induces proteinuria (6) (7) (8) (9) . These previous reports and our data support the assertion that the glomerular changes in mice or rats induced by increases in sFlt-1 or decreases of VEGF-A are similar to those seen in women with preeclampsia.
Possible side effects of VEGF-A and PlGF in human beings with preeclampsia
Considering the side effects of VEGF-A and PlGF when these molecules are administered to human beings with preeclampsia, we should consider the potential action of the vascular permeability of both molecules. As women with preeclampsia commonly show general edema, the administration of VEGF-A or PlGF may induce lung edema, which is a serious condition leading to maternal and fetal death. Therefore, we should choose angiogenetic drugs with a weaker action on vascular permeability. It is reported that PIGF-2 has a lower vascular permeability activity than VEGF-A (10, 11). The other possible side effects are the development of new blood vessels in non-targeted tissues, for example, in the retina, and growth of tumors (12) . Fortunately, up until now, no serious side effects due to an angiogenesis agent were recognized in the clinical trials in which VEGF-A was administered in human beings with coronary artery disease or peripheral vascular disease (12) . However, the effect of administration of VEGF-A or PlGF in preeclamptic women might be different from that in previous studies, because relative large doses of VEGF-A or PlGF will be needed for compensating the anti-angiogenetic effect of abnormally increased sFlt-1.
Limitations
In our experimental model, neither VEGF 164 nor PlGF-2 had an effect on the proteinuria induced by high dose Ad m-sFlt-1 administration. Compared with previous reports in which the administration of VEGF-A ameliorated the amount of proteinuria (13, 14) , in our study, the administered dose was smaller and administration duration was shorter. In a future study, we will examine the effects of VEGF-A and PlGF on proteinuria induced by Ad m-sFlt-1 using higher doses of VEGF-A and PlGF for a longer treatment duration than in the current study.
We abandoned our experimental plan of administering a higher dose (3 x 10 9 PFU) of Ad m-sFlt-1, because preterm deliveries at less than day 16.5 or 17.5 of gestation occurred in some mice when a high dose (2 x 10 9 PFU) of Ad m-sFlt-1 were administered. If we had tried the higher dose, we could have produced a more severe preeclamptic model showing the tendency for preterm delivery.
The use of PlGF-1 rather than PlGF-2 would have a better pharmacokinetic profile and therefore more likely to reach target organs like the kidney, because PlGF-1 lacks the heparin binding domain (15) . Likewise with regards to VEGF, the human VEGF 121 or human VEGF 165 might have been better than the mouse VEGF 164 (13) . However, since we created mice preeclamptic model using mouse sFlt-1, but not human sFlt-1, and since we tried to evaluate the effects of mouse VEGF-A and mouse PlGF-2 on hypertension and proteinuria induced by
Ad m-sFlt-1, we only picked VEGF 164 and PlGF-2.
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